Protiva Biotherapeutics, Inc.

Arbutus Biopharma Corporation

Other

The United States of America, as Represented by the Secretary, Department of Health and Human Services

The University of British Columbia

Alnylam Pharmaceuticals, Inc.

The United States Army Medical Research and Materiel Command

Ian MacLachlan

Lorne Ralph Palmer

Adam Judge

James Heyes

Lloyd B Jeffs

Amy C H Lee

Ed Yaworski

Kieu Lam

Edward D Yaworski

Marjorie Ann Robbins

Cory Giesbrecht

Vandana Sood

Stephen P Reid

Lisa E Hensley

Thomas W Geisbert

Ellen Grace Ambegia

Snorri S Thorgeirsson

Marcia MacDonald

Yun-Han Lee

Magdalena Maslowski

Noelle Giesbrecht, Legal Representative

Ammen P Dhillon

Amy C Lee

Mark Wood

Alan Martin

Roger W Graham

Nicholas Michael Snead

Emily P Thi

Phalgun Joshi

Raul J Ursic Bedoya

Jennifer L Cross

Susan De Jong

Elliott Kagan

John Finn

Ian C Mortimer

Patrick M S Tam

The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.

Lipid formulations for delivery of therapeutic agents

The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.

Liposomal apparatus and manufacturing methods

The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.

Lipid formulations for nucleic acid delivery

The present invention provides compositions comprising therapeutic nucleic acids such as siRNA that target Hepatitis B virus (HBV) gene expression, lipid particles comprising one or more (e.g., a combination) of the therapeutic nucleic acids, and methods of delivering and/or administering the lipid particles (e.g., for treating HBV infection and/or HDV infection in humans).

Compositions and methods for silencing hepatitis B virus gene expression

Rich tooling is provided for REST application development that integrates the exploration of a REST API, modeling of data types and the REST API, and the generation of artifacts using the modeled REST API and data types.

Lipid encapsulating interfering RNA

Lipid formulations for delivery of therapeutic agents to solid tumors

The present invention provides compositions comprising siRNA molecules that target Marburg virus (MARV) gene expression, lipid particles comprising one or more (e.g., a combination) of the siRNA molecules, and methods of delivering and/or administering the lipid particles, for the purposes of treating MARV infection.

Compositions and methods for silencing marburg virus gene expression

Lipid compositions for nucleic acid delivery

The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).

Compositions and methods for silencing apolipoprotein C-III expression

The present invention provides therapeutic nucleic acids such as interfering RNA (e.g., siRNA) that target the expression of genes associated with tumorigenesis and/or cell transformation, lipid particles (e.g., nucleic acid-lipid particles) comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles, e.g., for the treatment of a cell proliferative disorder such as cancer.

Compositions and methods for silencing genes expressed in cancer

Growing community of inventors

Mission, Canada

Ian MacLachlan